Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up

Francesca Palandri, Fausto Castagnetti, Nicoletta Testoni, Simona Luatti, Giulia Marzocchi, Simona Bassi, Massimo Breccia, Giuliana Alimena, Ester Pungolino, Giovanna Rege-Cambrin, Riccardo Varaldo, Maurizio Miglino, Giorgina Specchia, Eliana Zuffa, Felicetto Ferrara, Monica Bocchia, Giuseppe Saglio, Fabrizio Pane, Daniele Alberti, Giovanni MartinelliMichele Baccarani, Gianantonio Rosti

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients. Design and Methods: We conducted a phase II trial of imatinib 600 mg daily in patients with chronic myeloid leukemia in blast crisis. The return to chronic phase was defined as

Original languageEnglish
Pages (from-to)1792-1796
Number of pages5
JournalHaematologica
Volume93
Issue number12
DOIs
Publication statusPublished - Dec 2008

Keywords

  • Blast crisis
  • Chronic myeloid leukemia
  • Imatinib
  • Long-term
  • Outcome

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up'. Together they form a unique fingerprint.

Cite this